HELIX DIAGNOSTICS
Pharmacogenomics (PGx) Cancer Panel
Panel Description
Many chemotherapeutic agents and supportive care medications are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.
This panel evaluates 12 genes associated with response to cancer chemotherapeutics and associated supportive care medications. These include antiemetics, antifungals, antineoplastics, fluoropyrimidines, immunosuppressants, platelet-stimulating agents, proton pump inhibitors, and uric acid inhibitors. Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.
Genes Tested (12)
Important Panel Information
Turnaround time: 7-10 days
Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Cancer chemotherapeutics and associated supportive care medications which include antiemetics, antifungals, antineoplastics, fluoropyrimidines, immunosuppressants, platelet-stimulating agents, proton pump inhibitors, and uric acid inhibitors.
All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.